ANDA 219535, held by Anthea Pharma. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 219535 (Lidocaine Hydrochloride), held by Anthea Pharma, was first approved by FDA on Apr 2, 2025, with 1 approved supplement and 0 published complete response letters.
Lidocaine hydrochloride injection is indicated in adult and pediatric patients for the production of local or regional anesthesia or analgesia for surgery, dental, and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations of lidocaine hydrochloride injection is recommended for each type of block indicated to produce local or regional or anesthesia or analgesia. Lidocaine hydrochloride injection contains lidocaine, an amide local anesthetic.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 2, 2025 | Original application | Approved | None posted |
| Lidocaine Hydrochloride1% · injectable;injection | Lidocaine Hydrochloride | Rx |
| Lidocaine Hydrochloride2% · injectable;injection | Lidocaine Hydrochloride | Rx |
| Oct 2, 2025 | Supplement 7Manufacturing | Approved | None posted |
| Apr 2, 2025 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters